0
Clinical Investigations: ASTHMA |

Ambulatory Use of Inhaled β2-Agonists for the Treatment of Asthma in Quebec*: A Population-Based Utilization Review

Régis Blais, PhD; Jean-Pierre Grégoire, PhD; Rachel Rouleau, MSc; André Cartier, MD; Jacques Bouchard, MD; Louis-Philippe Boulet, MD; and the Comité de revue de l’utilisation des médicaments
Author and Funding Information

Affiliations: *From the Département d’administration de la santé et Groupe de recherche interdisciplinaire en santé (Dr. Blais), Université de Montréal, Montréal; Faculté de pharmacie et Groupe de recherche en Épidémiologie (Dr. Grégoire), Université Laval, Québec city; Centre universitaire de santé de l’Estrie (Ms. Rouleau), Sherbrooke; Service de pneumologie (Dr. Cartier), Hôpital du Sacré-Coeur de Montréal, Montréal; Centre hospitalier St-Joseph de La Malbaie (Dr. Bouchard), La Malbaie; and Centre de pneumologie de l’Hôpital Laval (Dr. Boulet), Institut de cardiologie et de pneumologie de l’Université Laval, Québec City, Québec, Canada. ,  A complete list of participants is given in the Appendix.

Correspondence to: Régis Blais, PhD, Groupe de recherche interdisciplinaie en santé, Université de Montréal, PO Box 6128, Station Centre-ville, Montréal, Québec, Canada H3C 3J7; e-mail: Regis.Blais@umontreal.ca



Chest. 2001;119(5):1316-1321. doi:10.1378/chest.119.5.1316
Text Size: A A A
Published online

Study objectives: To assess whether the utilization of inhaled short-acting β2-agonists (ISAB) and inhaled long-acting β2-agonists (ILAB) for the treatment of asthma was appropriate according to the 1996 Canadian Asthma Consensus Conference recommendations.

Design: Population-based retrospective drug utilization review using pharmacists’ billing data of the Prescription Drug Insurance Plan administered by the Quebec health insurance board. However, the database used did not contain complete patient clinical information to accurately assess severity of asthma.

Setting: Province of Quebec, Canada.

Patients: Persons who received at least one outpatient prescription of ISAB (age range, 5 to 45 years) or ILAB (age range, 12 to 45 years) for the treatment of asthma between August 1997 and April 1998.

Measurements: Percentages of patients whose use was appropriate according to three criteria regarding the average daily dose of ISAB (criterion 1), the renewal interval of ILAB (criterion 2), and the concomitant daily use of corticosteroids for the expected length of utilization of ILAB (criterion 3).

Results: Overall proportions of appropriate use according to criterion 1 were as follows: 75% (without inhaled corticosteroids [ICS]) and 84% and 43% (with one or more than one prescription of ICS, respectively). Appropriateness was slightly higher for female patients, younger patients (5 to 18 years old), and those treated by pediatricians. However, appropriateness was only 9% among patients who received at least two prescriptions of ISAB during the study period. The proportion of appropriate use was 19% according to criterion 2 and 15% according to criterion 3; there were few differences by gender or by age, but the appropriateness according to criterion 2 was somewhat higher for patients of respirologists.

Conclusion: Compared to the 1996 Canadian asthma consensus conference recommendations, ISAB are overused, ICS are underused, and ILAB are often used improperly. Close collaboration between health professionals and patients is essential to improve the pharmacotherapy of asthma.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543